ArticleClinical and experimental medicine2023
miR-548 predicts clinical prognosis and functions as a tumor promoter in gastric cancer.
Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 5 citations in OpenAlex.
- Integrative Molecular Profiling of miR-548f-3p in Triple-Negative Breast Cancer HighlightsInternational journal of molecular sciences · 2026Article
- Isoliquiritigenin Suppresses Oral Squamous Cell Carcinoma Progression by Targeting FABP5-Mediated Lipid Metabolism: Association with the circPOLB/miR-548ae-3p/C-MYC Axis.Oncology research · 2026Article
- miR-548t-3p impairs nuclear mechanosensitivity and focal adhesion via lamin A/C downregulation.Biophysical journal · 2025Article
- Dysregulation of adipocytokines via the hsa-miR-548ay-3p/PPARγ signaling pathway leads to cardiac fibrosis.Scientific reports · 2025Article
- miR-548ac and miR-378j as Potential Diagnostic Biomarkers in Gastric Cancer: A Case-Control Study.Middle East journal of digestive diseases · 2025Article
- Circ_0003356 suppresses gastric cancer growth through targeting the miR-668-3p/SOCS3 axis.World journal of gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous pieces of evidence have demonstrated the functional role of miR-548 in various cancers. The expression and function of miR-548 in gastric cancer were investigated in the present study. A total of 123 gastric cancer patients were included and provided paired gastric cancer tissues and matched normal tissues. RT-qPCR was used to detect the expression of miR-548. CCK8 assay was used to evaluate cell proliferation, and Transwell assay was applied to assess cell migration and invasion. The clinical significance of miR-548 was estimated by a series of statistical analyses. miR-548 was found to be upregulated in gastric cancer, which was associated with the lymph node metastasis and TNM stage of patients. Patients with relatively high miR-548 expression possessed bad survival. miR-548 was identified as a prognostic indicator of gastric cancer. miR-548 was also found to promote the proliferation, migration, and invasion of gastric cancer. Upregulated miR-548 was involved in the progression of gastric cancer and predicted the prognosis of patients. Inhibition of miR-548 might be a novel therapeutic strategy for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.